Exclusive Summary

• Targeting a global market of over 1.28 billion hypertensive patients, it serves as a chronic medication ensuring stable, high-volume recurring sales for distributors.
• As a highly lipophilic 3rd-generation CCB, it offers smooth 24-hour BP control with lower incidence of peripheral edema than amlodipine, solving clear clinical pain points.
• With originator patents fully expired, targeting Lacidipine (rather than the heavily saturated Amlodipine) provides a smart, differentiated cardiovascular portfolio addition for clients.
• Leveraging standard 4mg dosing and China's highly cost-effective supply chain, the Distribution model promises exceptional profit margins for overseas partners.